Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | LTA4H | P09960 | 1/20 | 0.41 |
| ▸ | HTR3E | A5X5Y0 | 1/20 | 0.38 |
| ▸ | HTR3B | O95264 | 1/20 | 0.38 |
| ▸ | HTR3A | P46098 | 1/20 | 0.38 |
| ▸ | HTR3D | Q70Z44 | 1/20 | 0.38 |
| ▸ | HTR3C | Q8WXA8 | 1/20 | 0.38 |
| ▸ | BACE1 | P56817 | 1/20 | 0.38 |
| ▸ | HRH4 | Q9H3N8 | 1/20 | 0.37 |
| ▸ | KMT2A | Q03164 | 3/20 | 0.37 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.36 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.36 |
| ▸ | GLA | P06280 | 1/20 | 0.36 |
| ▸ | GAA | P10253 | 1/20 | 0.36 |
| ▸ | TSHR | P16473 | 1/20 | 0.36 |
| ▸ | GRM5 | P41594 | 1/20 | 0.35 |
| ▸ | NPC1 | O15118 | 1/20 | 0.35 |
| ▸ | RAB9A | P51151 | 1/20 | 0.35 |
| ▸ | HTT | P42858 | 2/20 | 0.35 |
| ▸ | RPS6KA5 | O75582 | 1/20 | 0.34 |
| ▸ | MEN1 | O00255 | 1/20 | 0.34 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL30178291 | 1.00 | LTA4H (0.41) | LTA4HHTR3EHTR3BHTR3AHTR3D | |
| SCHEMBL31229913 | 0.76 | LTA4H (0.39) | LTA4HHTR3EHTR3BHTR3AHTR3D | |
| SCHEMBL3960228 | 0.75 | LTA4H (0.52) | LTA4HALDH1A1KDM4ENPC1RAB9A | |
| SCHEMBL323983 | 0.74 | KMT2A (0.44) | LTA4HHTR3EHTR3BHTR3AHTR3D | |
| SCHEMBL21295269 | 0.74 | LTA4H (0.38) | LTA4HHTR3EHTR3BHTR3AHTR3D | |
| SCHEMBL1165560 | 0.74 | LTA4H (0.38) | LTA4HHTR3EHTR3BHTR3AHTR3D | |
| SCHEMBL1446732 | 0.74 | LTA4H (0.38) | LTA4HHTR3EHTR3BHTR3AHTR3D | |
| SCHEMBL13296647 | 0.74 | LTA4H (0.38) | LTA4HHTR3EHTR3BHTR3AHTR3D | |
| SCHEMBL13378103 | 0.74 | RPS6KA5 (0.38) | LTA4HHTR3EHTR3BHTR3AHTR3D | |
| SCHEMBL18225730 | 0.74 | LTA4H (0.38) | LTA4HHTR3EHTR3BHTR3AHTR3D |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 207 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-4460709-A | Process for producing oxygen-containing organic compounds | AGENCY OF INDUSTRIAL SCIENCE & TECHNOLOGY (JP) | 1984-07-17 | — | — | US | claimed |
| US-20250230157-A1 | AZABENZIMIDAZOLES AND THEIR USE AS AMPA RECEPTOR MODULATORS | RAPPORT THERAPEUTICS, INC. | 2025-07-17 | — | — | US | disclosed |
| WO-2024105364-A1 | HETEROCYCLIC INHIBITORS OF CDC-LIKE KINASES | CURADEV PHARMA LTD (GB) | 2024-05-23 | — | — | WO | disclosed |
| EP-3445762-B1 | SUBSTITUTED BICYCLIC HETEROCYCLIC COMPOUNDS | BRISTOL MYERS SQUIBB CO (US) | 2023-09-13 | — | — | EP | disclosed |
| US-20230212160-A1 | 2,4,6-TRI-SUBSTITUTED PYRIMIDINE COMPOUNDS AS ATR KINASE INHIBITORS | BEIJING TIDE PHARMACEUTICAL CO., LTD. (CN) | 2023-07-06 | — | — | US | disclosed |
| US-20230212160-A1 | 2,4,6-TRI-SUBSTITUTED PYRIMIDINE COMPOUNDS AS ATR KINASE INHIBITORS | BEIJING TIDE PHARMACEUTICAL CO., LTD. (CN) | 2023-07-06 | — | — | US | disclosed |
| US-20230192683-A1 | FUSED RING COMPOUNDS, PREPARATION METHOD THEREFOR, PHARMACEUTICAL COMPOSITIONS AND USE THEREOF | GUANGZHOU FERMION TECHNOLOGY CO., LTD. (CN) | 2023-06-22 | — | — | US | disclosed |
| US-11643421-B2 | Process for the preparation of tricyclic PI3K inhibitor compounds and methods for using the same for the treatment of cancer | GENENTECH, INC. (US) | 2023-05-09 | — | — | US | disclosed |
| WO-2022268025-A1 | ATR INHIBITOR AND USE THEREOF | 成都苑东生物制药股份有限公司 | 2022-12-29 | — | — | WO | disclosed |
| WO-2022263548-A1 | 3-SUBSTITUTED 1H-PYRROLO[2,3-B]PYRIDINE AS GRK5 MODULATORS | LEAD DISCOVERY CENTER GMBH (DE) | 2022-12-22 | — | — | WO | disclosed |
| US-20030139393-A1 | Substituted homopiperidinyl benzimidazole analogues as fundic relaxants | JANSSEN PHARMACEUTICA N.V. (BE) | 2003-07-24 | — | — | US | disclosed |
| US-6518263-B1 | Imidazo[4,5-b]pyridiniummethyl-containing cephem compounds having broad antibacterial spectrum | SHIONOGI & CO., LTD. (JP) | 2003-02-11 | — | — | US | disclosed |
| EP-1250337-A1 | SUBSTITUTED HOMOPIPERIDINYL BENZIMIDAZOLE ANALOGUES AS FUNDIC RELAXANTS | Janssen Pharmaceutica N.V. (BE) | 2002-10-23 | — | — | EP | disclosed |
| EP-1134222-A1 | IMIDAZO[4,5-b]PYRIDINIUMMETHYL-CONTAINING CEPHEM COMPOUNDS HAVING BROAD ANTIBACTERIAL SPECTRUM | SHIONOGI & CO., LTD. (JP) | 2001-09-19 | — | — | EP | disclosed |
| WO-2001046189-A1 | SUBSTITUTED HOMOPIPERIDINYL BENZIMIDAZOLE ANALOGUES AS FUNDIC RELAXANTS | JANSSEN PHARMACEUTICA N.V. (BE) | 2001-06-28 | — | — | WO | disclosed |
| EP-0232623-B1 | 1-CARBACEPHALOSPORIN ANTIBIOTICS | ELI LILLY AND COMPANY (US) | 1993-03-17 | — | — | EP | disclosed |
| US-4892942-A | 1-CARBA (DETHIA)CEPHALOSPORINS | ELI LILLY AND COMPANY (US) | 1990-01-09 | — | — | US | disclosed |
| US-4791106-A | 1-Carbacephalosporin antibiotics | ELI LILLY AND COMPANY (US) | 1988-12-13 | — | — | US | disclosed |
| EP-0232623-A1 | 1-Carbacephalosporin antibiotics | ELI LILLY AND COMPANY (US) | 1987-08-19 | — | — | EP | disclosed |
| US-4460709-A | Process for producing oxygen-containing organic compounds | AGENCY OF INDUSTRIAL SCIENCE & TECHNOLOGY (JP) | 1984-07-17 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (5 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-11643421-B2 | Process for the preparation of tricyclic PI3K inhibitor compounds and methods for using the same for the treatment of cancer | PIK3CA, PIK3CD, PIK3CB | LTA4H 3486/4885HTR3E 3510/4885HTR3B 2689/4885 |
| US-20230212160-A1 | 2,4,6-TRI-SUBSTITUTED PYRIMIDINE COMPOUNDS AS ATR KINASE INHIBITORS | ATR, CHEK2, CHEK1 | LTA4H 4208/4885HTR3E 4383/4885HTR3B 3971/4885 |
| US-20030139393-A1 | Substituted homopiperidinyl benzimidazole analogues as fundic relaxants | HRH2, CBR1, HTR1D | LTA4H 1696/4885HTR3E 64/4885HTR3B 69/4885 |
| US-20230192683-A1 | FUSED RING COMPOUNDS, PREPARATION METHOD THEREFOR, PHARMACEUTICAL COMPOSITIONS AND USE THEREOF | SSTR4, SSTR3, NPY4R | LTA4H 487/4885HTR3E 399/4885HTR3B 158/4885 |
| US-20250230157-A1 | AZABENZIMIDAZOLES AND THEIR USE AS AMPA RECEPTOR MODULATORS | GRIN1, GRIN2B, GRIN3A | LTA4H 2119/4885HTR3E 1171/4885HTR3B 456/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.